Dominik Juskanič1,2,3, Jana Poláková Mištinová4, Samuel Hollý5, Monika Sekerešová6, Kamil Koleják6, Lukáš Pátrovič5. 1. JESSENIUS-Diagnostic Center, Nitra, Slovakia. juskanic.dominik@jessenius.sk. 2. Medical Faculty, Comenius University in Bratislava, Bratislava, Slovakia. juskanic.dominik@jessenius.sk. 3. Faculty Hospital, Nitra, Slovakia. juskanic.dominik@jessenius.sk. 4. Medical Faculty, Comenius University in Bratislava, Bratislava, Slovakia. 5. JESSENIUS-Diagnostic Center, Nitra, Slovakia. 6. Faculty Hospital, Nitra, Slovakia.
Abstract
OBJECTIVE: Oncometabolite D-2-hydroxyglutarate (2HG) is pooled in isocitrate dehydrogenase (IDH)-mutant glioma cells. Detecting 2HG by MR spectroscopy (MRS) has been proven viable in the last decade but has not entirely found its way into the clinical routine. This study aimed to explore the adoption of 2HG MRS while acknowledging factors that influence its performance in the clinical environment. METHODS: Thirty-nine MR spectra were acquired and reported prospectively in patients with suspected glioma using a 3 T system with Mescher-Garwood point-resolved spectroscopy (MEGA-PRESS) sequence utilizing averaged free induction decay (FID) signals. Postprocessing and evaluation of spectra were performed with jMRUI and LCModel. 2HG concentration estimates, 2HG/Cr ratio, together with quality measures, including Cramér-Rao lower bounds (CRLBs), full-width at half-maximum (FWHM) values, and signal-to-noise ratio (SNR) were calculated using LCModel. Immunohistochemistry and genomic analysis results used as a ground truth were available for 15 patients. RESULTS: The threshold for test positivity was set according to the ROC curve at 1 mM. Calculated sensitivity was 57.14% (95% CI 0.20-0.88), specificity 87.5% (95% CI 0.46-0.99), positive predictive value 80%, and negative predictive value 70%. Overall diagnostic accuracy was 73.33% (95% CI 0.45-0.92). The 2HG/Cr ratio with the cutoff value 0.085 significantly improved sensitivity and overall diagnostic accuracy [85.71%, 95% CI 0.42-1.00 and 86.67%, (95% CI 0.60-0.98), respectively]. CONCLUSION: Multiple factors compromising spectral quality in the clinical adoption of edited 2HG MRS resulted in diminished sensitivity but clinically acceptable specificity. Furthermore, the 2HG/Cr ratio performs better than the sole 2HG concentration estimate in the pre-operative setting.
OBJECTIVE: Oncometabolite D-2-hydroxyglutarate (2HG) is pooled in isocitrate dehydrogenase (IDH)-mutant glioma cells. Detecting 2HG by MR spectroscopy (MRS) has been proven viable in the last decade but has not entirely found its way into the clinical routine. This study aimed to explore the adoption of 2HG MRS while acknowledging factors that influence its performance in the clinical environment. METHODS: Thirty-nine MR spectra were acquired and reported prospectively in patients with suspected glioma using a 3 T system with Mescher-Garwood point-resolved spectroscopy (MEGA-PRESS) sequence utilizing averaged free induction decay (FID) signals. Postprocessing and evaluation of spectra were performed with jMRUI and LCModel. 2HG concentration estimates, 2HG/Cr ratio, together with quality measures, including Cramér-Rao lower bounds (CRLBs), full-width at half-maximum (FWHM) values, and signal-to-noise ratio (SNR) were calculated using LCModel. Immunohistochemistry and genomic analysis results used as a ground truth were available for 15 patients. RESULTS: The threshold for test positivity was set according to the ROC curve at 1 mM. Calculated sensitivity was 57.14% (95% CI 0.20-0.88), specificity 87.5% (95% CI 0.46-0.99), positive predictive value 80%, and negative predictive value 70%. Overall diagnostic accuracy was 73.33% (95% CI 0.45-0.92). The 2HG/Cr ratio with the cutoff value 0.085 significantly improved sensitivity and overall diagnostic accuracy [85.71%, 95% CI 0.42-1.00 and 86.67%, (95% CI 0.60-0.98), respectively]. CONCLUSION: Multiple factors compromising spectral quality in the clinical adoption of edited 2HG MRS resulted in diminished sensitivity but clinically acceptable specificity. Furthermore, the 2HG/Cr ratio performs better than the sole 2HG concentration estimate in the pre-operative setting.
Authors: Twinkal C Pansuriya; Ronald van Eijk; Pio d'Adamo; Maayke A J H van Ruler; Marieke L Kuijjer; Jan Oosting; Anne-Marie Cleton-Jansen; Jolieke G van Oosterwijk; Sofie L J Verbeke; Daniëlle Meijer; Tom van Wezel; Karolin H Nord; Luca Sangiorgi; Berkin Toker; Bernadette Liegl-Atzwanger; Mikel San-Julian; Raf Sciot; Nisha Limaye; Lars-Gunnar Kindblom; Soeren Daugaard; Catherine Godfraind; Laurence M Boon; Miikka Vikkula; Kyle C Kurek; Karoly Szuhai; Pim J French; Judith V M G Bovée Journal: Nat Genet Date: 2011-11-06 Impact factor: 41.307
Authors: Changho Choi; Sandeep K Ganji; Ralph J DeBerardinis; Kimmo J Hatanpaa; Dinesh Rakheja; Zoltan Kovacs; Xiao-Li Yang; Tomoyuki Mashimo; Jack M Raisanen; Isaac Marin-Valencia; Juan M Pascual; Christopher J Madden; Bruce E Mickey; Craig R Malloy; Robert M Bachoo; Elizabeth A Maher Journal: Nat Med Date: 2012-01-26 Impact factor: 53.440
Authors: Parker L Sulkowski; Christopher D Corso; Nathaniel D Robinson; Susan E Scanlon; Karin R Purshouse; Hanwen Bai; Yanfeng Liu; Ranjini K Sundaram; Denise C Hegan; Nathan R Fons; Gregory A Breuer; Yuanbin Song; Ketu Mishra-Gorur; Henk M De Feyter; Robin A de Graaf; Yulia V Surovtseva; Maureen Kachman; Stephanie Halene; Murat Günel; Peter M Glazer; Ranjit S Bindra Journal: Sci Transl Med Date: 2017-02-01 Impact factor: 19.319
Authors: Zachary J Reitman; Genglin Jin; Edward D Karoly; Ivan Spasojevic; Jian Yang; Kenneth W Kinzler; Yiping He; Darell D Bigner; Bert Vogelstein; Hai Yan Journal: Proc Natl Acad Sci U S A Date: 2011-02-02 Impact factor: 12.779